Organism: Homo sapiens
Gene: 39614_at
Selected probe(set): 213358_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39614_at (213358_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):6.253563
Number of Samples:36 / 74

Experimental	precursor-B-ALL study 1 (t(1;19)(q23,q13))
	Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):5.52258
Number of Samples:2 / 13

Experimental	precursor-B-ALL study 2 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	T-ALL study 2
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG).

Relative Expression (log2-ratio):4.994282
Number of Samples:6 / 5

Experimental	precursor-B-ALL study 3 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	precursor-B-ALL study 3 (MLL-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):4.72276
Number of Samples:2 / 27

Experimental	precursor-B-ALL study 2 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	precursor-B-ALL study 2 (hyperdiploid)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Dutch Childhood Oncology Group (DCOG).

Relative Expression (log2-ratio):4.461297
Number of Samples:6 / 29

Experimental	precursor-B-ALL study 3 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	T-ALL study 3
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):4.1367283
Number of Samples:6 / 4

Experimental	precursor-B-ALL study 3 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	precursor-B-ALL study 3 (BCR-ABL)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):4.090555
Number of Samples:6 / 17

Experimental	precursor-B-ALL study 3 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	precursor-B-ALL study 3 (hyperdiploid)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):3.9268131
Number of Samples:2 / 21

Experimental	precursor-B-ALL study 2 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	precursor-B-ALL study 2 (TEL-AML1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Dutch Childhood Oncology Group (DCOG).

Relative Expression (log2-ratio):-3.8617716
Number of Samples:30 / 2

Experimental	precursor-B-ALL study 2 (unspecified)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (no specific subtype). Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	precursor-B-ALL study 2 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).

Relative Expression (log2-ratio):-3.7822762
Number of Samples:2 / 2

Experimental	zalypsis study 2
	OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control	untreated OPM1 cell sample
	OPM1 multiple myeloma cells untreated.